Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells

ABSTRACT: Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells

PROVIDER: PRJNA642172 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12098200_1.fastq.gz	Fastqsanger.gz
	SRR12098200_2.fastq.gz	Fastqsanger.gz
	SRR12099700_1.fastq.gz	Fastqsanger.gz
	SRR12099700_2.fastq.gz	Fastqsanger.gz
	SRR12098201_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 155

Similar Datasets

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [ATAC-seq]

Project description:Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [ATAC-seq]

| PRJNA642174 | ENA

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [RNA-seq]

Project description:Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [RNA-seq]

| PRJNA642175 | ENA

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [ATAC-seq]

Project description:We report the application of paired Assay for Transposase-Accessible Chromatin (ATAC-seq) and RNA-seq data to profile the regulatory landscape and expression of 5 primary Plasma Cell (PC), 28 Multiple Myeloma (MM) PC as well as 5 cell lines samples. Findings discriminated MM and MM subgroup-specific changes such as the exclusive overexpression of CCND1 and CCND2 oncogenes. DNA accessibility changes were correlated to gene expression in a topologically constrained manner to elucidate novel enhancer - promoter interactions, genes and pathways critical for myeloma biology and developmentally activated or de novo formed enhancers. Additionally, the MM subgroup-specific TF network dependencies were studied to help identify prognostic markers. Finally, we discover and functionally validate the critical enhancer that regulates ectopic expression of CCND2 in MM.

2021-06-29 | GSE153379 | GEO

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [RNA-seq]

2021-06-29 | GSE153380 | GEO

Small RNA Next Generation Sequencing of healthy and myeloma plasma cells

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare the small RNA profile of healthy and myeloma plasma cells derived from non cancer donors and newly diagnosed myeloma patients Methods: Plasma Cell small RNA profiles of 3 healthy plasma cells and 3 newly diagnosed myeloma patients were generated by deep sequencing, using Illumina GAIIx. Conclusions: Our study represents the first detailed analysis of small RNA sequencing in plasma cells. The optimized data analysis workflows reported here should provide a framework for comparative investigations of expression profiles. Our results show that NGS offers a comprehensive quantitative and qualitative evaluation of small RNA content within the healthy and myeloma plasma cells.

2018-02-28 | GSE95539 | GEO

miRNA profiling of multiple myeloma, MGUS, multiple myeloma cell lines and normal plasma cells

Project description:miRNA profiling in multiple myeloma - microRNAs represent a class of noncoding regulators of gene expression implicated in several biological and pathophysiological processes, including cancer. We investigate here their role in multiple myeloma using miChip-arrays interrogating 559 miRNAs in 92 purified myeloma-, MGUS-, normal plasma cell- and myeloma cell line samples. Impact on gene expression is assessed by Affymetrix U133 2.0 DNA-microarrays in 741 samples including two cohorts of 332 and 345 myeloma patients; chromosomal aberrations are assessed by iFISH, survival for 247 and 345 patients undergoing up-front high-dose therapy and autologous stem cell transplantation. Compared to normal plasma cells, 67/559 (12%) miRNAs are differentially expressed with fold changes of 4.6 to -3.1 in myeloma-, 20 (3.6%) in MGUS-samples, and three (0.5%) between MGUS- and myeloma-samples. Expression of miRNAs is associated with biological and pathophysiological parameters, i.e. proliferation, chromosomal aberrations, e.g. t(4;14), tumor mass, and gene expression-based high-risk scores. This holds true for target-gene signatures of regulated mRNAs. miRNA-expression confers prognostic significance for event-free (72/559) and overall survival (69/559), as do respective target-gene signatures. In conclusion, the miRNome of myeloma confers a pattern of small changes of individual miRNAs compared to normal plasma cells impacting on gene expression, biological functions, and survival.

2014-01-09 | E-MTAB-1363 | biostudies-arrayexpress

Transcription profiling of bone marrow plasma cells from 320 newly diagnosed multiple myeloma patients

Project description:In order to identify relevant, molecularly defined subgroups in Multiple Myeloma (MM), gene expression profiling (GEP) was performed on purified CD138+ plasma cells of 320 newly diagnosed myeloma patients included in the Dutch-Belgian/German HOVON-65/ GMMG-HD4 trial using Affymetrix Gene Chip U133 plus 2.0 arrays. Hierarchical clustering identified 10 distinct subgroups. Bone marrow plasma cell samples were obtained from 320 newly diagnosed multiple myeloma patients included in a large multicenter, prospective, randomized phase III trial (HOVON65/GMMG-HD4). Purified myeloma plasma cells samples with a monoclonal plasma cell purity > 80% were used for analysis.

2010-06-27 | E-GEOD-19784 | biostudies-arrayexpress

Transcription profiling of human plasma cell samples from multiple myeloma patients

Project description:Samples in this series are pre-treatment bone marrow aspirates from multiple myeloma patients. Experiment Overall Design: Samples in this series are: Experiment Overall Design: 1. CD-138-selected plasma cells from bone marrow of patients with newly diagnosed multiple myeloma subsequently treated with high dose therapy and stem cell transplants termed Total Therapy 2 (pre-treatment TT2) Experiment Overall Design: 2. CD-138-selected plasma cells from bone marrow of patients with newly diagnosed multiple myeloma subsequently treated with Total Therapy 3 (pre treatment TT3). Experiment Overall Design: Overall Design: Experiment Overall Design: Gene expression signatures were used to: 1) develop unsupervised hierarchical cluster classes; 2) establish links with outcome following stem cell transplantation

2008-06-13 | E-GEOD-2658 | biostudies-arrayexpress

Transcription profiling by array of human CD138 purified bone marrow plasma cells from relapsed multiple myeloma patients

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of relapsed multiple myeloma patients

2017-02-09 | E-MTAB-4715 | biostudies-arrayexpress

Transcription profiling by array of human CD138 purified bone marrow plasma cells from patients with multiple myeloma

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of previously untreated multiple myeloma patients

2017-02-09 | E-MTAB-4717 | biostudies-arrayexpress